Basic information Description Features In vitro In vivo Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Inhibitors DNA damage PARP inhibitors BMN 673

1/1

BMN 673

$ 1.00 /1KG

Min. Order1G
Purity98%
Cas No1207456-01-6
Supply Ability100KG
Update time2019-07-06

career henan chemical co

career henan chemical co

6YR

China

show more

Chemical Properties

Product Name	BMN 673
CAS No	1207456-01-6
EC-No
Min. Order	1G
Purity	98%
Supply Ability	100KG
Release date	2019/07/06

AD68

BMN 673 Basic information

Description Features In vitro In vivo

Product Name:	BMN 673
Synonyms:	BMN 673;LT-673;(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one;(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-Methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;Talazoparib;3H-Pyrido[4,3,2-de]phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-;Talazoparib (BMN 673);(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one BMN673
CAS:	1207456-01-6
MF:	C19H14F2N6O
MW:	380.3508664
EINECS:
Product Categories:	API;Inhibitors
Mol File:	1207456-01-6.mol

BMN 673 Chemical Properties

density

1.63

Safety Information

MSDS Information

BMN 673 Usage And Synthesis

Description	Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.58 nM in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features	Most potent and selective PARPi reported thus far.
In vitro	BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors.
In vivo	In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner.

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book